Design and Synthesis of Potent and Selective α4β7 Integrin Antagonists

Interactions of the integrins α4β7 with its cognate ligand mucosal addressin cell adhesion molecule-1 (MAdCAM-1) play a crucial role in the development of mucosa-associated lymphoid organs, in the generation of mucosal immune responses, and in diverse pathological processes such as chronic inflammatory bowel disease and type I diabetes. Using a previously developed spatial screening technique we describe the development of potent and selective α4β7 integrin antagonists based on the domain 1 Leu-Asp-Thr (LDT) sequence of MAdCAM-1 that is essential for α4β7 integrin binding. A library of homodetic cyclic penta- and hexapeptides was synthesized presenting the pharmacophoric LDT-sequence in different conformations. The cyclic hexapeptide P10 cyclo(Leu-Asp-Thr-Ala-d-Pro-Ala) inhibits α4β7 integrin mediated cell adhesion to MAdCAM-1 effectively. Further optimization of the lead structure P10 resulted in cyclic hexapeptides with enhanced activity. The compounds P25 cyclo(Leu-Asp-Thr-Ala-d-Pro-Phe), P28 cyclo(Leu-Asp-Thr-Asp-d-Pro-Phe), P29 cyclo(Leu-Asp-Thr-Asp-d-Pro-His), and P30 cyclo(Leu-Asp-Thr-Asp-d-Pro-Tyr) strongly inhibited α4β7 integrin mediated cell adhesion to MAdCAM-1, but they did not affect binding of the closely related α4β1 integrin to VCAM-1.